Carol Burns is a serial entrepreneur with extensive experience working in the cardiovascular sector. Ms. Burns is currently the CEO of Cagent Vascular, (Wayne, PA) which has developed and commercialized a novel angioplasty balloon incorporating Serration Technology with co-founders Robert Giasolli and Dr. Peter Schneider. This co-founding team previously started Intact Vascular (acquired by Philips) where Ms. Burns served as the founding CEO and raised $17M in capital to develop the Tack Endovascular System, a Nitinol implant in a multi-loaded catheter for treatment of peripheral artery disease. Prior to Intact Vascular, she was the first employee of another peripheral vascular company, Embrella Cardiovascular. Ms. Burns served as the Vice President of Product and Business Development which developed an embolic protection device for use in Transcatheter Aortic Valve Replacement (TAVR) procedures (acquired by Edwards Lifesciences). Ms. Burns also worked at Animas Corporation (acquired by Johnson and Johnson) as the Sr. Director of International Sales and Marketing. She served as the Managing Director, Europe at Ventrica, Inc. (acquired by Medtronic) and held various management positions at Guidant Corporation working in the cardiac and vascular surgery division where she played a key role in the launch of the first US marketed endovascular abdominal aortic aneurysm device and an endoscopic vessel harvesting product for coronary artery bypass surgery. Ms. Burns received her BSN degree from The College of New Jersey, in Ewing, New Jersey.